studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 947A
progressive decrease in ammonia concentration was observed
in both groups, being higher in OP group at each time point,
without significant differences. Decrease in ammonia in the first
24h in the OP group [-20.40 μmol/L (-39.20, -2.80); median
(IQR)] was twice that of the placebo group [-11.88 μmol/L
(-36.75, 26.35)], without statistical significance. The subanalysis
by Child-Pugh score showed a statistically significant
ammonia decrease in Child-Pugh C treated patients at 36 h, as
well as in the time normalized area under the curve (TN-AUC)
0-120h in the OP group [40.16 μmol/L (37.7, 42.6 )] vs placebo
group [ 65.5 μmol/L (54, 126); p=0.036]. A progressive
decrease in plasma glycine and glutamine were observed in
the treated group as compared to the placebo group. These
differences reached statistical significance after 24 h of treatment
and were maintained thereafter. Glutamine decrease
associated with the appearance of phenylacetylglutamine in
urine: u-PAG accumulated TN-AUC 12-120h placebo [5768
μmol (1769,8808)] vs TN-AUC 12-120h OP [106851μmol
(78802, 146666); p50 mmol/L). Ammonemia was higher in patients
with HE than in those without (108 (95%CI: 86-123) vs 57
(95%CI: 50-81), p=0.0004). In patients with HE, ammonemia
was significantly correlated to severity of HE assessed by GCS
(p=0.001). Overall, 34 HE patients experienced worsening of
their neurological status during hospitalisation. Ammonemia
at admission was significantly higher in those patients (128
(95%CI: 108-147) vs 87 (95%CI: 64-110), p=0.007). In multivariate
analysis, parameters independently associated with
worsening of neurological status were MELD score and ammonia
levels at admission (p=0.01 and 0.02, respectively). Conclusion:
Ammonia levels at admission are correlated with the
severity of HE and with outcome in cirrhotic patients with HE.
Disclosures:
Marika Rudler - Speaking and Teaching: Gilead, Mayoly
Thierry Poynard - Grant/Research Support: Gilead; Stock Shareholder: BioPredictive
Nicolas Weiss - Speaking and Teaching: Norgine, Alpha Wasserman
The following authors have nothing to disclose: Simona Tripon, Maxime Mallet,
Denis Monneret, Francoise Imbert-Bismut, Dominique Thabut
1511
Use of betablockers, previous hepatic encephalopathy
and low albumin levels as risk factors of portal vein
thrombosis in a cohort of cirrhotic patients
Marta Lopez Gomez 1 , Elba Llop 1 , Angela Puente 2 , Juan de la
Revilla 1 , Carlos Fernández-Carrillo 1 , Fernando Pons 1 , Jose Luis
Martinez 1 , Natalia Fernández 1 , Maria Trapero 1 , Javier Crespo 2 ,
José Luís Calleja 1 ; 1 Gastroenterology and Hepatology, Hospital
Universitario Puerta de Hierro (MADRID. SPAIN), Pozuelo de
Alarcon, Spain; 2 Hospital Universitario Marqués de Valdecilla,
Santander, Spain
Portal vein thrombosis(PVT) is a complication of liver cirrosis(LC).
The aim of our study was to evaluate anual incidence
of PVT and related risk factors.Methods: We retrospectively
reviewed clinical and radiological data collected prospectively
of consecutive cirrhotic patients included in the database
of two Universitary Hospitals. Patients out of Milan criteria
HCC, known PVT, TIPS and pregnancy were excluded. All
patients with ultrasound diagnosis of PVT underwent MR or
CTangiography.Results: From September 2013 to September
2014, 747 cirrhotic patients were reviewed, 179 had exclusion
criteria. Baseline characteristics are described in Table
1. 23(4%) patients presented PVT during the inclusion period.
Significant differences between patients with/without PVT
were observed in: albumin (3.4SD0.8vs4.0SD0.5;p